Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I, Steven N, Lorigan P, Plummer R, Patel P, Psarelli E, Olsson-Brown A, Shaw H, Leyvraz S, Handley L, Rawcliffe C, Nathan P. Sacco JJ, et al. Among authors: danson s. Eur J Cancer. 2024 May;202:114009. doi: 10.1016/j.ejca.2024.114009. Epub 2024 Mar 11. Eur J Cancer. 2024. PMID: 38547774 Free article. Clinical Trial.
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Gupta A, Love S, Schuh A, Shanyinde M, Larkin JM, Plummer R, Nathan PD, Danson S, Ottensmeier CH, Lorigan P, Collins L, Wise A, Asher R, Lisle R, Middleton MR. Gupta A, et al. Among authors: danson s. Ann Oncol. 2014 May;25(5):968-74. doi: 10.1093/annonc/mdu054. Epub 2014 Feb 24. Ann Oncol. 2014. PMID: 24567366 Free article. Clinical Trial.
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, Rao A, Fusi A, Danson S, Eccles B, Carser J, Brown CO, Steven N, Bhattacharyya M, Brown E, Gonzalez M, Highley M, Pickering L, Kumar S, Waterston A, Burghel G, Demain L, Baker E, Wulff J, Qian W, Twelves S, Middleton M, Corrie P. Dayimu A, et al. Among authors: danson s. Eur J Cancer. 2024 Jan;196:113455. doi: 10.1016/j.ejca.2023.113455. Epub 2023 Nov 24. Eur J Cancer. 2024. PMID: 38029480 Free article. Clinical Trial.
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P. Corrie PG, et al. Among authors: danson sj. Lancet Oncol. 2014 May;15(6):620-30. doi: 10.1016/S1470-2045(14)70110-X. Epub 2014 Apr 15. Lancet Oncol. 2014. PMID: 24745696 Free article. Clinical Trial.
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Larkin J, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG. Ahmad SS, et al. Among authors: danson s. Melanoma Res. 2015 Oct;25(5):432-42. doi: 10.1097/CMR.0000000000000185. Melanoma Res. 2015. PMID: 26225580 Free PMC article.
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
Coen O, Corrie P, Marshall H, Plummer R, Ottensmeier C, Hook J, Bell S, Sagoo GS, Meads D, Bestall J, Velikova G, Gallagher FA, Smith A, Howard H, Mason E, Katona E, Silva S, Collinson M, Rodwell S, Danson S. Coen O, et al. Among authors: danson s. BMC Cancer. 2021 Jul 1;21(1):761. doi: 10.1186/s12885-021-08509-w. BMC Cancer. 2021. PMID: 34210290 Free PMC article. Clinical Trial.
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, Arkenau T, Evans TRJ, Danson S, Symeonides SN, Veal GJ, Klencke BJ, Kowalski MM, Banerji U. Kristeleit R, et al. Among authors: danson s. Br J Cancer. 2023 Jul;129(1):38-45. doi: 10.1038/s41416-023-02279-x. Epub 2023 Apr 29. Br J Cancer. 2023. PMID: 37120671 Free PMC article. Clinical Trial.
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.
Khan F, Ottensmeier C, Popat S, Dua D, Dorey N, Ellis S, Szabo M, Upadhyay S, Califano R, Chan S, Lee L, Ali CW, Nicolson M, Bates AT, Button M, Chaudhuri A, Mulvenna P, Shaw HM, Danson SJ. Khan F, et al. Among authors: danson sj. Eur J Cancer. 2014 Jul;50(10):1717-1721. doi: 10.1016/j.ejca.2014.03.001. Epub 2014 Apr 10. Eur J Cancer. 2014. PMID: 24726055
123 results